REG - Gelion PLC - Director appointment - Dr Graham Cooley

GelionAnnouncement

06/01/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250106:nRSF1311Sa&default-theme=true

RNS Number : 1311S  Gelion PLC  06 January 2025

6 January 2025

Gelion plc

("Gelion" or "the Company")

Director appointment - Dr Graham Cooley

Further to the announcement made on 18 December 2024, the Board of Gelion plc,
the global energy storage innovator, is pleased to announce the appointment of
Dr Graham Cooley, as Non-Executive Director of the Company with immediate
effect. Dr Cooley's appointment strengthens the Company's capabilities and
corporate governance for the next stage of its growth.

Dr Graham Cooley brings a wealth of relevant experience and knowledge to the
Gelion Board through his background in the power, energy storage and hydrogen
sectors over more than 35 years. He was previously Business Development
Manager at National Power plc, the UK's largest power generator, and CEO of
ITM Power plc, the first hydrogen related company quoted on AIM. Dr Cooley has
been involved in a wide range of corporate transactions, including ones that
have raised over £600m for UK cleantech SMEs. He also has a track record of
forging industrial partnerships and entering new markets. He has been an
active investor in AIM UK cleantech companies for over a decade and holds a
PhD in Materials Physics, an MBA and has several fellowship appointments.

Dr Cooley has been appointed as a member of the Company's Audit Committee and
Remuneration Committee.

Steve Mahon, Chairman of Gelion, commented: "I am delighted to be welcoming
Graham to the Gelion board. He brings extensive and very relevant experience
which will prove invaluable as we continue to progress toward
commercialisation of our battery technologies."

John Wood, Chief Executive of Gelion, commented: "Graham brings his exemplary
full scope entrepreneurial perspective to the Gelion board, with the
combination of the depth of personal understanding he has of delivering
successful commercialisation and value development running innovation
companies, along with his experience with investment markets. Welcome Graham!"

Further disclosures pursuant to Rule 17 and Schedule Two, paragraph (g) of the
AIM Rules for Companies:

Dr Graham Edward Cooley

The following information regarding the appointment of Dr Graham Edward
Cooley, aged 61, is disclosed under Schedule 2(g) of the AIM Rules for
Companies:

 Current directorships and/or partnerships               Past directorships and/or partnerships (within the last five years)
 Light Science Technologies Holdings plc                 ITM Power plc
 Brigantia Capital Ltd                                   H2 Green Ltd
 Cadent Gas Limited                                      ITM Power UK Limited (formerly ITM Power (Trading) Limited)
 Cap-XX Limited                                          ITM Power Pty Limited
 Quadgas Holdco Limited                                  ITM Linde Electrolysis GmbH
 Quadgas Investments Bidco Limited                       ITM Power ApS
 Quadgas Midco Limited                                   ITM Power Service GmbH
 Quadgas Pledgeco Limited                                ITM Service GmbH
 Yelooc Limited                                          ITM Power (Shelfco) Limited
 LSTH Trustee Limited                                    ITM Power (Research) Limited
 Light Science Technologies Ltd                          Motive Fuels Limited
 Tomtech (UK) Limited                                    Nanosun Limited
 LSTH IFB Limited                                        Orkney Hydrogen Trading Ltd
 UK Circuits and Electronics Solutions Limited           Renewable UK Association
 UK Circuits and Electronics Solutions Holdings Limited
 Quadgas Holdings Topco Limited (UK)
 Quadgas Holdings Topco Limited (Jersey)

 

Nanosun Limited entered into director led administration on 6 February 2024
and on the same date, a pre-pack sale of the business and certain assets was
completed.

Dr Cooley currently holds 666,666 Ordinary Shares, representing 0.45% of the
Company's issued Ordinary Share capital.

CONTACTS

 Gelion plc                                                              via Alma

 John Wood, CEO

 Amit Gupta, CFO

 Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)  +44 20 7220 0500
 Neil McDonald / Seamus Fricker / Adam Rae (Corporate Finance)

 Louise Talbot (Sales)

 Oberon Capital (Joint Broker)                                           +44 20 3179 5300
 Nick Lovering, Mike Seabrook, Adam Pollock

 Alma Strategic Communications (Financial PR Adviser)                    +44 20 3405 0205

 Justine James / Hannah Campbell / Will Ellis Hancock                    gelion@almastrategic.com (mailto:gelion@almastrategic.com)

 

About Gelion

Gelion ("gel: ion") is a global energy storage innovator, supporting the
transition to a more sustainable economy by commercialising two globally
important next generation technologies: Lithium-Sulfur (LiS) and Zinc-based
(Zn) hybrid cells to electrify mobile and stationary applications. Gelion plc
(the Group) is listed on the London Stock Exchange's Alternative Investment
Market and wholly owns Australia based Gelion Technologies Pty Ltd and UK
based OXLiD Ltd. Gelion is designing and delivering innovative battery
technologies and integrated systems solutions to enable that transition and
return value for its customers and investors.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOABJMATMTTMBIA